Literature DB >> 10711352

The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leucocytes to vascular endothelium in vitro.

R Lever1, J R Hoult, C P Page.   

Abstract

1. The effects of an unfractionated heparin preparation (Multiparin), a low molecular weight heparin preparation (Fragmin) and a selectively O-desulphated derivative of heparin lacking anticoagulant activity, have been investigated for their effects on the adhesion of human polymorphonuclear leucocytes (PMNs) to cultured human umbilical vein endothelial cells (HUVECs) in vitro. The effect of poly-L-glutamic acid, a large, polyanionic molecule was also studied. 2. Unfractionated heparin (50-1000 U ml-1), the O-desulphated derivative (0.3-6 mg ml-1) and the low molecular weight heparin (50 U-1000 U ml-1) all inhibited significantly the adhesion of 51Cr labelled PMNs to HUVECs stimulated with interleukin-1 beta (IL-1 beta; 10 U ml-1), bacterial lipopolysaccharide (LPS; 2.5 micrograms ml-1) or tumour necrosis factor-alpha (TNF-alpha; 125 U ml-1) for 6 h, whereas poly-L-glutamic acid had no effect. In addition, the three heparin preparations in the same concentration range inhibited significantly the adhesion of f-met-leu-phe-stimulated PMNs to resting HUVECs. 3. The effects of unfractionated heparin upon the expression of adhesion molecules intercellular adhesion molecule-1 (ICAM-1) and E-selection were also investigated, as were the effects of unfractionated heparin upon adhesion of human PMNs to previously stimulated HUVECs. Heparin had little effect upon levels of expression of these adhesion molecules on stimulated HUVECs. However, a profound effect upon PMN adhesion to previously stimulated HUVECs was demonstrated using the same preparation, suggesting that inhibition of adhesion molecule expression is not a major component of the described inhibitory effects of heparin. 4. Pre-incubation of PMNs with heparin followed by washing inhibited their adhesion to HUVECs, under different conditions of cellular activation, implying that heparin can bind to these cells and exert its anti-adhesive effects even when not directly present in the system. 5. These observations would suggest that both heparin and a low molecular weight heparin are capable of inhibiting adhesion of human PMNs to endothelial cells, an effect not dependent solely upon the polyanionic nature of these molecules, nor dependent upon their ability to act as anticoagulants.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10711352      PMCID: PMC1571874          DOI: 10.1038/sj.bjp.0703099

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  24 in total

Review 1.  Adhesion interactions involved in eosinophil migration through vascular endothelium.

Authors:  A J Wardlaw; G M Walsh; F A Symon
Journal:  Ann N Y Acad Sci       Date:  1996-10-31       Impact factor: 5.691

Review 2.  Leucocyte adhesion molecules in host defence against infection.

Authors:  E J Brown; F P Lindberg
Journal:  Ann Med       Date:  1996-06       Impact factor: 4.709

3.  The effect of heparin and related proteoglycans on allergen and PAF-induced eosinophil infiltration.

Authors:  E A Seeds; J Hanss; C P Page
Journal:  J Lipid Mediat       Date:  1993-07

Review 4.  More to "heparin" than anticoagulation.

Authors:  U Lindahl; K Lidholt; D Spillmann; L Kjellén
Journal:  Thromb Res       Date:  1994-07-01       Impact factor: 3.944

5.  The effect of inhaled heparin and related glycosaminoglycans on allergen-induced eosinophil infiltration in guinea-pigs.

Authors:  E A Seeds; A P Horne; D J Tyrrell; C P Page
Journal:  Pulm Pharmacol       Date:  1995 Apr-Jun

6.  Effect of heparin, dermatan sulfate, and related oligo-derivatives on human polymorphonuclear leukocyte functions.

Authors:  G Bazzoni; A Beltrán Nuñez; G Mascellani; P Bianchini; E Dejana; A Del Maschio
Journal:  J Lab Clin Med       Date:  1993-02

7.  Effects of heparin and its desulfated derivatives on leukocyte-endothelial adhesion.

Authors:  L Silvestro; I Viano; M Macario; D Colangelo; G Montrucchio; S Panico; R Fantozzi
Journal:  Semin Thromb Hemost       Date:  1994       Impact factor: 4.180

8.  Lysolecithin-induced alteration of subendothelial heparan sulfate proteoglycans increases monocyte binding to matrix.

Authors:  P Sivaram; J C Obunike; I J Goldberg
Journal:  J Biol Chem       Date:  1995-12-15       Impact factor: 5.157

Review 9.  Therapeutic uses of heparin beyond its traditional role as an anticoagulant.

Authors:  D J Tyrell; S Kilfeather; C P Page
Journal:  Trends Pharmacol Sci       Date:  1995-06       Impact factor: 14.819

10.  Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1).

Authors:  M S Diamond; R Alon; C A Parkos; M T Quinn; T A Springer
Journal:  J Cell Biol       Date:  1995-09       Impact factor: 10.539

View more
  18 in total

1.  Influence of low molecular weight heparin (certoparin) and unfractionated heparin on the release of cytokines from human leukocytes.

Authors:  M Köller; F Kutscha-Lissberg; J Brom; G Weidinger; G Muhr
Journal:  Inflammation       Date:  2001-10       Impact factor: 4.092

2.  Long-term anticoagulation in Kawasaki disease: Initial use of low molecular weight heparin is a viable option for patients with severe coronary artery abnormalities.

Authors:  Cedric Manlhiot; Leonardo R Brandão; Zeeshanefatema Somji; Amy L Chesney; Catherine MacDonald; Rebecca C Gurofsky; Tarun Sabharwal; Nita Chahal; Brian W McCrindle
Journal:  Pediatr Cardiol       Date:  2010-04-30       Impact factor: 1.655

3.  Inhibition of inflammation induced shedding of the endothelial glycocalyx with low molecular weight heparin.

Authors:  Herbert H Lipowsky; Anne Lescanic
Journal:  Microvasc Res       Date:  2017-03-27       Impact factor: 3.514

4.  Heparin protects against septic mortality via apoE-antagonism.

Authors:  Kelley I Chuang; Briana Leung; Nancy Hsu; Hobart W Harris
Journal:  Am J Surg       Date:  2011-07-08       Impact factor: 2.565

5.  The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis.

Authors:  Eric P Schmidt; Yimu Yang; William J Janssen; Aneta Gandjeva; Mario J Perez; Lea Barthel; Rachel L Zemans; Joel C Bowman; Dan E Koyanagi; Zulma X Yunt; Lynelle P Smith; Sara S Cheng; Katherine H Overdier; Kathy R Thompson; Mark W Geraci; Ivor S Douglas; David B Pearse; Rubin M Tuder
Journal:  Nat Med       Date:  2012-07-22       Impact factor: 53.440

6.  The effects of heparin on the adhesion of human peripheral blood mononuclear cells to human stimulated umbilical vein endothelial cells.

Authors:  A Smailbegovic; R Lever; C P Page
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

Review 7.  The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development.

Authors:  Essam Elsayed; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2003-02       Impact factor: 2.300

8.  Low-dose heparin for the prevention of post-ERCP pancreatitis: a randomized placebo-controlled trial.

Authors:  O Barkay; E Niv; E Santo; R Bruck; A Hallak; F M Konikoff
Journal:  Surg Endosc       Date:  2008-01-24       Impact factor: 4.584

Review 9.  Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease.

Authors:  Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Expert Opin Investig Drugs       Date:  2008-04       Impact factor: 6.206

10.  Effect of a low molecular weight heparin molecule, dalteparin, on cellular apoptosis and inflammatory process in an incisional wound-healing model.

Authors:  Ali Civelek; Koray Ak; Ozlem Kurtkaya; Atike Tekeli; Selim Isbir; Erol Nargileci; Sinan Arsan; Aydin Sav
Journal:  Surg Today       Date:  2007-04-30       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.